OSI Systems Inc. (OSIS) Company Profile
OSI Systems, Inc., together with its subsidiaries, designs and manufactures electronic systems and components for homeland security, healthcare, defense, and aerospace markets worldwide. The company operates in three divisions: Security, Healthcare, and Optoelectronics and Manufacturing. The Security division provides security and inspection systems under the Rapiscan Systems name. Its products include baggage and parcel inspection, cargo and vehicle inspection, hold baggage screening, and people screening products to search for weapons, explosives, drugs, and other contraband, as well as for the verification of cargo manifests for monitoring the export and import of controlled materials. This division also offers various turn-key security screening solutions under the S2 trade name. The Healthcare division provides patient monitoring, diagnostic cardiology, and anesthesia delivery and ventilation systems under the Spacelabs name that are used in critical care, emergency, and perioperative areas within hospitals, as well as physician?s offices, medical clinics, and ambulatory surgery centers. The Optoelectronics and Manufacturing division offers optoelectronic devices for the aerospace and defense, avionics, medical imaging and diagnostic, renewable energy, biochemistry analysis, pharmaceutical, nanotechnology, telecommunications, construction, and homeland security markets under the OSI Optoelectronics name; and electronics manufacturing services to original equipment manufacturers under the OSI Electronics name. This division also provides laser-based remote sensing devices to detect and classify vehicles in toll and traffic management systems under the OSI Laserscan name; blood pressure cuffs and unifusors under the Statcorp Medical name; and solid-state laser products for aerospace, defense, telecommunication, and medical applications under the OSI LaserDiode trade name. The company was founded in 1987 and is headquartered in Hawthorne, California.
News about OSIS
3 Cheap Growth Stocks With Upside Catalysts
As the market wraps up first quarter earnings season, results have been undeniably good. More than three-quarters (78%) of the companies in the S&P 500 have beaten earnings expectations, the highest percentage since FactSet began tracking it in 2...Read More>>>
Cellectis: Will Focus On Universal CAR-T Payoff?
I believe gene therapy will become a mainstay in treating, and maybe curing, many of our most devastating and intractable illnesses. Scott Gottlieb, FDA Commissioner Cellectis S.A. (CLLS) announced news in 2015 that made me sit up and take notice ...Read More>>>
3 Things In Biotech, May 20: You Want Some Good News?
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious. Welcome to another edition of "3 Things In ...Read More>>>
Reader Inquiry: What's In Store For Corcept Therapeutics?
Shares of Corcept Therapeutics (CORT) have risen by over 175% since I originally recommended the stock as a Core Buy in biotech. Key points to the original thesis included the following: Their Cushing's syndrome franchise continued to experience imp...Read More>>>
Will 'Public Shaming' Sink Celgene?
Source: NPR To stave off generic competition drug makers often get creative. They seek new uses for old drugs, seek patent extensions and refuse to provide samples to generic rivals. Allergan (AGN) even sold Restasis (dry eye) patents to the St. Re...Read More>>>